Aberdeen Group Portfolio holdings
Aberdeen Group is a British wealth and investment company, created in 2017 when Standard Life merged with Aberdeen Asset Management. In 2018 it agreed to sell the Standard Life insurance business to Phoenix Group, shifting the company from insurance toward asset management. After selling the Standard Life name to Phoenix Group in 2021 it rebranded as abrdn, a vowel-free name that drew criticism, and in 2025 it went back to Aberdeen. Among its businesses is Interactive Investor, a British retail investing service that runs on subscriptions, which it bought in 2022.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$319M |
| 2 |
Amazon
AMZN
|
+$165M |
| 3 |
Microsoft
MSFT
|
+$110M |
| 4 |
HONA
Honeywell Aerospace
HONA
|
+$92.7M |
| 5 |
UnitedHealth
UNH
|
+$69.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Honeywell
HON
|
+$182M |
| 2 |
RTX Corp
RTX
|
+$97.9M |
| 3 |
Marvell Technology
MRVL
|
+$81.2M |
| 4 |
GE Vernova
GEV
|
+$80.7M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$73.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 34.75% |
| 2 | Healthcare | 12.68% |
| 3 | Consumer Discretionary | 10.96% |
| 4 | Communication Services | 10.76% |
| 5 | Financials | 9.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
326
Lockheed Martin
LMT
$133B
| $31.2M | 0.04% |
61,309
+13,927
| +29% | +$7.53M |
2017 Q3
35 quarters
|
|
327
JFrog
FROG
$10.6B
| $31M | 0.04% |
340,820
-150,572
| -31% | -$9.8M |
2024 Q2
8 quarters
|
|
328
Tetra Tech
TTEK
$10.5B
| $30.9M | 0.04% |
1,068,968
-353,245
| -25% | -$10.4M |
2020 Q1
25 quarters
|
|
329
Take-Two Interactive
TTWO
$39.9B
| $30.9M | 0.04% |
123,425
-9,574
| -7% | -$2.11M |
2018 Q1
33 quarters
|
|
330
Charles River Laboratories
CRL
$15.6B
| $30.8M | 0.04% |
135,799
+21,972
| +19% | +$3.91M |
2021 Q2
20 quarters
|
|
331
DexCom
DXCM
$33B
| $30.8M | 0.04% |
456,802
-20,496
| -4% | -$1.37M |
2018 Q4
30 quarters
|
|
332
Sysco
SYY
$37B
| $30.7M | 0.04% |
367,443
+16,563
| +5% | +$1.25M |
2017 Q3
35 quarters
|
|
333
DELISTED
Crinetics Pharmaceuticals
CRNX
| $30.7M | 0.04% |
820,395
| – | – |
2023 Q4
10 quarters
|
|
334
Arch Capital
ACGL
$36.1B
| $30.7M | 0.04% |
315,799
+30,926
| +11% | +$2.92M |
2017 Q3
35 quarters
|
|
335
CBRE Group
CBRE
$40.7B
| $30.3M | 0.04% |
224,729
-47,280
| -17% | -$6.51M |
2017 Q3
35 quarters
|
|
336
Occidental Petroleum
OXY
$57.3B
| $30M | 0.04% |
617,077
+22,044
| +4% | +$1.25M |
2017 Q3
35 quarters
|
|
337
Oculis Holding
OCS
$406M
| $30M | 0.04% |
2,159,809
+412,863
| +24% | +$9.37M |
2023 Q4
10 quarters
|
|
338
Axon Enterprise
AXON
$31.1B
| $29.8M | 0.04% |
53,080
-2,481
| -4% | -$1.04M |
2019 Q2
28 quarters
|
|
339
Veralto
VLTO
$28.5B
| $29.2M | 0.04% |
329,242
-10,398
| -3% | -$903K |
2023 Q4
10 quarters
|
|
340
M&T Bank
MTB
$32.3B
| $28.8M | 0.04% |
121,094
+1,633
| +1% | +$357K |
2017 Q3
35 quarters
|
|
341
Nasdaq
NDAQ
$59.7B
| $28.8M | 0.04% |
365,582
+33,474
| +10% | +$2.94M |
2017 Q3
35 quarters
|
|
342
Arcutis Biotherapeutics
ARQT
$4.28B
| $28.8M | 0.04% |
1,098,411
+453,345
| +70% | +$10.6M |
2023 Q4
10 quarters
|
|
343
CRH
CRH
$65.7B
| $28.8M | 0.04% |
268,862
-78,881
| -23% | -$8.68M |
2024 Q2
8 quarters
|
|
344
EyePoint Inc
EYPT
$34.1M
| $28.7M | 0.04% |
2,008,802
+270,424
| +16% | +$3.62M |
2024 Q4
6 quarters
|
|
345
Marathon Petroleum
MPC
$107B
| $28.5M | 0.04% |
111,616
+1,317
| +1% | +$323K |
2017 Q3
35 quarters
|
|
346
Alnylam Pharmaceuticals
ALNY
$21.6B
| $28.4M | 0.04% |
94,450
-43,881
| -32% | -$13.2M |
2018 Q2
32 quarters
|
|
347
Everus Construction Group
ECG
$4.07B
| $28.2M | 0.04% |
169,856
-87,852
| -34% | -$12.9M |
2025 Q3
3 quarters
|
|
348
NeoGenomics
NEO
$2.22B
| $28.2M | 0.04% |
1,931,525
-95,368
| -5% | -$920K |
2025 Q1
5 quarters
|
|
349
Northern Trust
NTRS
$32.2B
| $28.1M | 0.04% |
161,519
-16,248
| -9% | -$2.68M |
2017 Q3
35 quarters
|
|
350
Sandisk
SNDK
$115B
| $28M | 0.04% |
12,313
-1,130
| -8% | -$1.61M |
2025 Q4
2 quarters
|
|
Similar funds
Aberdeen Group's Q2 2026 Portfolio in Review
As of Q2 2026, Aberdeen Group held 978 positions worth $71.2B, up 15% from $61.9B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Aberdeen Group's Q2 2026 filing shows 47 new, 453 increased, 412 reduced and 44 closed positions. Its largest new stake was Honeywell Aerospace: 420,093 shares worth $92.9M. The largest sale was Honeywell, an estimated $182M.
By sector, the portfolio is most concentrated in Technology at 35% of assets, up from 31% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q2 2026 buy was Honeywell Aerospace: 420,093 shares worth $92.9M.
- Aberdeen Group added most to Tesla in Q2 2026, an estimated $319M increase.
- Aberdeen Group's biggest Q2 2026 reduction was RTX Corp, cutting an estimated $97.9M.
- Aberdeen Group fully exited Honeywell in Q2 2026, selling an estimated $182M.
- Aberdeen Group's ten largest holdings make up 37% of its $71.2B portfolio in Q2 2026.
- Aberdeen Group opened 47 new positions and closed 44 in Q2 2026.
- Aberdeen Group's portfolio value rose 15% quarter-over-quarter to $71.2B.
Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.